Promiscuous HER-2/Neu CD4 T cell epitopes

Details Promiscuous HER-2/Neu CD4 T cell epitopes Promiscuous HER-2/Neu CD4 T cell epitopes

2011-07-05

2011-07-05

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

Reexamination Certificate

active

07972602

ABSTRACT:
The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

REFERENCES:
patent: 6664370 (2003-12-01), Cheever et al.
patent: 7060284 (2006-06-01), Kaumaya et al.
patent: 2002/0055614 (2002-05-01), Cheever
patent: 2004/0121946 (2004-06-01), Fikes et al.
patent: 2007/0071827 (2007-03-01), Kaumaya et al.
patent: 1568373 (2005-08-01), None
patent: WO 01/08636 (2001-02-01), None
patent: WO 01/41787 (2001-06-01), None
patent: WO 01/74855 (2001-11-01), None
Peoples et al (J of Clinical Oncology, Oct. 2005, 23:7536-7545).
Lin et al (Molecular Therapy, Aug. 2004, 10: 290-301).
Peoples et al (J of Clinical Oncology, Oct. 2005, 23:7536-7545).
Lin et al (Molecular Therapy, Aug. 2004, 10: 290-301).
Fujita et al (Eur. J. Immunology, 1998, 28:305-316).
Talken et al (J of Immunology, 2001, 167:562-568).
Fujita et al (Eur. J. Immunology, 1998, 28:305-316).
Talken et al (J of Immunology, 2001, 167:562-568).
Peoples et al (J of Clinical Oncology, Oct. 2005, 23:7536-7545).
Lin et al (Molecular Therapy, Aug. 2004, 10: 290-301).
Keilholz et al., “Immune Monitoring of T-Cell Responses in Cancer Vaccine Development,” 2006, Clin. Cancer Res., 12, 7 Suppl., pp. 2346s-2352s.
Wierecky et al., “Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients,” 2006, Cancer Res., 66, 11, 5910-5918.
Kobayashi, Hiroya et al.; “Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2
euTumor Antigen”; 2000,Cancer Research, vol. 60, pp. 5228-5236.
Sotiriadou, R. et al.; “Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope”; 2001,British Journal of Cancer, vol. 85, No. 10, pp. 1527-1534.

Affiliated with

Also associated with

Rating

Promiscuous HER-2/Neu CD4 T cell epitopes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Promiscuous HER-2/Neu CD4 T cell epitopes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Promiscuous HER-2/Neu CD4 T cell epitopes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2673398